You are here

Article Text

Article menu

Download PDFPDF

An older man with a rare cause of heart failure
Free
  1. Nilson Lopez-Ruiz1,
  2. Kenny Mauricio Galvez2,
  3. Juan Camilo Perez3
  1. 1Division of Cardiology, Hospital Pablo Tobon Uribe, Medellin, Colombia
  2. 2Division of Haematology, Hospital Pablo Tobon Uribe, Medellin, Colombia
  3. 3Department of Pathology, Hospital Pablo Tobon Uribe, Medellin, Colombia
  1. Correspondence to Dr Nilson Lopez-Ruiz, nlopez{at}hptu.org.co

http://dx.doi.org/10.1136/bcr-2013-202377

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Description

    A previously healthy 74-year-old man presented with symptoms of heart failure over the last 10 months. Initial tests revealed raised levels of brain natriuretic peptide (617 pg/mL) and a low-voltage ECG. An echocardiogram showed symmetric left ventricular (LV) hypertrophy, systolic dysfunction (ejection fraction 35%; figure 1A, video 1), restrictive filling pattern and decreased global longitudinal strain (figure 1B). As the cardiomyopathy aetiology was unclear, he underwent further testing. A cardiac MRI demonstrated diffuse subendocardial delayed myocardial enhancement after gadolinium injection (figure 1C) and amyloid deposits were found on endomyocardial biopsy (figure 1D). The serum κ/λ free-light chains (FLC) ratio was 2.4 (increased) and a bone marrow biopsy ruled out multiple myeloma. The final diagnosis was cardiac amyloid light-chain (AL) amyloidosis and he was started on cyclophosphamide, thalidomide and dexamethasone. His congestive symptoms improved with diuretics. At 15 months of follow-up, he is in New York Heart Association class II.

    Figure 1
    Figure 1

    (A) Transthoracic echocardiography showing a non-dilated left ventricular cavity with increase of septal and posterior wall thickness. Myocardial ‘granular sparkling’ is also noticeable. (B) Bulls-eye view quantitative data for global and segmental wall motion of the left ventricle. Apical deformation is preserved (normal−18±2%) while the remaining segments are completely abnormal. (C) Cardiac MRI demonstrating diffuse myocardial delayed enhancement (red arrows) after gadolinium injection. (D) Endomyocardial biopsy stained with Congo red and viewed with polarising microscopy. Amyloid deposits exhibit apple-green birefringence. LV: left ventricle, RV: right ventricle.

    Video 1

    Transthoracic echocardiography showing reduced left ventricular ejection fraction, marked left ventricular wall thickening, and increased echogenicity of the myocardium.

    Only 5% of patients with unexplained cardiomyopathy are found to have amyloidosis.1 Amyloid infiltration of the heart results in increased LV thickening seen on echocardiography (associated with reduced ECG voltage).2 As this finding is indistinguishable from other causes of LV hypertrophy, the use of more advanced imaging techniques such as speckle-tracking echocardiography and cardiac MRI can provide non-invasive evidence suggestive of amyloid cardiomyopathy.3 However, the diagnosis of cardiac amyloidosis is only confirmed when the biopsy specimen stains with Congo red. In AL amyloidosis, λ or κ FLC is also detectable in serum or urine. Finally, the treatment involves the use of chemotherapy and/or autologous stem cell transplantation.

    Learning points

    • Cardiac amyloidosis should always be considered in patients without hypertension with left ventricle hypertrophy and low-voltage ECG.

    • Cardiac MRI provides strongly suggestive evidence of amyloid cardiomyopathy.

    References

    1. ↵
      1. Felker GM,
      2. Thompson RE,
      3. Hare JM,
      4. et al
      . Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077–84.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      1. Gertz MA,
      2. Comenzo R,
      3. Falk RH,
      4. et al
      . Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79:319–28.
      OpenUrlCrossRefPubMedWeb of Science
    3. ↵
      1. Esplin BL,
      2. Gertz MA
      . Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol 2013;38:53–96.
      OpenUrlCrossRefPubMed

    Footnotes

    • Contributors All authors were equally involved in the planning, execution, and reporting of the work.

    • Competing interests None.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.